Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21713193 | 1.00 | CAPN1 (0.46) | CAPN1GLP1RMEN1GAAKMT2A | |
| SCHEMBL31045346 | 1.00 | CAPN1 (0.46) | CAPN1GLP1RMEN1GAAKMT2A | |
| SCHEMBL27145930 | 1.00 | CAPN1 (0.46) | CAPN1GLP1RMEN1GAAKMT2A | |
| SCHEMBL27145928 | 1.00 | CAPN1 (0.46) | CAPN1GLP1RMEN1GAAKMT2A | |
| SCHEMBL27150954 | 1.00 | CAPN1 (0.46) | CAPN1GLP1RMEN1GAAKMT2A | |
| SCHEMBL22657805 | 0.91 | MEN1 (0.49) | GLP1RMEN1GAAKMT2AFOLH1 | |
| SCHEMBL22657806 | 0.91 | MEN1 (0.49) | GLP1RMEN1GAAKMT2AFOLH1 | |
| SCHEMBL16908998 | 0.91 | GLP1R (0.48) | CAPN1GLP1RMEN1GAAKMT2A | |
| SCHEMBL16909068 | 0.91 | GLP1R (0.48) | CAPN1GLP1RMEN1GAAKMT2A | |
| SCHEMBL24864615 | 0.90 | CAPN1 (0.45) | CAPN1GLP1RMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228726-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2021-07-29 | — | — | US | disclosed |
| US-11007275-B2 | Cryptophycin antibody conjugates for the treatment of cancer | SANOFI (FR) | 2021-05-18 | — | — | US | disclosed |
| US-11007275-B2 | Cryptophycin antibody conjugates for the treatment of cancer | SANOFI (FR) | 2021-05-18 | — | — | US | disclosed |
| US-20200093934-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2020-03-26 | — | — | US | disclosed |
| CN-110831633-A | Peptide linker and cryptophycin conjugate for therapy and preparation thereof | 赛诺菲 | 2020-02-21 | — | — | CN | disclosed |
| US-20200054760-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-02-20 | — | — | US | disclosed |
| US-20200054760-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007275-B2 | Cryptophycin antibody conjugates for the treatment of cancer | XPOT, CHMP4B, XPO5 | CAPN1 3801/4885GLP1R 3298/4885MEN1 356/4885 |
| US-20200054760-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CLSPN, RPN1, MRPL37 | CAPN1 696/4885GLP1R 2384/4885MEN1 690/4885 |
| US-20200093934-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CLSPN, RPN1, MRPL37 | CAPN1 696/4885GLP1R 2384/4885MEN1 690/4885 |
| US-20210228726-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CLSPN, RPN1, MRPL37 | CAPN1 696/4885GLP1R 2384/4885MEN1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.